investor.agios.com investor.agios.com

investor.agios.com

Overview- Agios

Annual Report and Proxy. Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. 160; 2.23. Aug 06, 2015. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. Aug 05, 2015. Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015. Jul 30, 2015.

http://investor.agios.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.AGIOS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.6 out of 5 with 11 reviews
5 star
8
4 star
2
3 star
1
2 star
0
1 star
0

Hey there! Start your review of investor.agios.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

5.7 seconds

CONTACTS AT INVESTOR.AGIOS.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Overview- Agios | investor.agios.com Reviews
<META>
DESCRIPTION
Annual Report and Proxy. Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. 160; 2.23. Aug 06, 2015. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. Aug 05, 2015. Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015. Jul 30, 2015.
<META>
KEYWORDS
1 agios
2 sitemap
3 about us
4 our science
5 pipeline
6 careers
7 media center
8 overview
9 press releases
10 events and presentations
CONTENT
Page content here
KEYWORDS ON
PAGE
agios,sitemap,about us,our science,pipeline,careers,media center,overview,press releases,events and presentations,in the news,publications,sec filings,corporate governance,analyst coverage,stock information,investor faq's,information request,e mail alerts
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Overview- Agios | investor.agios.com Reviews

https://investor.agios.com

Annual Report and Proxy. Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. 160; 2.23. Aug 06, 2015. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. Aug 05, 2015. Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015. Jul 30, 2015.

LINKS TO THIS WEBSITE

agios.com agios.com

Agios

http://www.agios.com/patients.php

About Cancers with IDH Mutations. David Schenkein, M.D. Chief Executive Officer. The people pictured here are some of the many friends and relatives of Agios employees who have been affected by cancer. All of us at Agios are passionate about transforming patients’ lives. This is our vision and what motivates, inspires, and drives us. AGIOS: THE OTHER SIDE OF POSSIBLE.

agios.com agios.com

Agios

http://www.agios.com/pipeline.php

Click below to learn more about our programs in IDH and PKR as well as other research into targets of interest to the fields of cancer metabolism and rare genetic disorders of metabolism. AGIOS: THE OTHER SIDE OF POSSIBLE.

agios.com agios.com

Agios

http://www.agios.com/scientific-community.php

Maintaining an Active Dialogue with the Scientific Community. Agios Pharmaceuticals was founded in 2007 as, we believe, the first biopharmaceutical company dedicated to the discovery and development of novel medicines the emerging field of cancer metabolism. Agios is actively engaged with scientific collaborators throughout the world working at the forefront of cancer metabolism and rare genetic disorders of metabolism. These collaborations have been instrumental in rapidly advancing our drug discove...

agios.com agios.com

Agios

http://www.agios.com/about.php

Our Values and Culture. In Our Words - The Blog. AGIOS: THE OTHER SIDE OF POSSIBLE.

agios.com agios.com

Agios

http://www.agios.com/index.php

Agios is passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders.

agios.com agios.com

Agios

http://www.agios.com/sitemap.php

About Cancers with IDH Mutations. Our Values and Culture. Founders and Scientific Advisors. Arete - In Our Words. Our Values and Culture. Arete - In Our Words. AGIOS: THE OTHER SIDE OF POSSIBLE.

agios.com agios.com

Agios

http://www.agios.com/careers-overview.php

Our Values and Culture. In Our Words - The Blog. Agios is looking for exceptional people who. Will help us discover the “other side of possible” for patients. Will succeed in a collaborative, innovative culture driven by scientific excellence. Want to work in a dynamic, casual environment with a company that offers competitive compensation and benefits, located in downtown Cambridge, Mass. If you would like to join our team, please review our open positions and apply directly through this website.

agios.com agios.com

Agios

http://www.agios.com/science-our-approach.php

Rare Genetic Disorders of Metabolism. Inspired by patients and frustrated by the limitations of conventional approaches to cancer treatment, Agios is forging a new and different path to treating cancer and rare genetic disorders by targeting cellular metabolism. Is needed to view the above animation. AGIOS: THE OTHER SIDE OF POSSIBLE.

UPGRADE TO PREMIUM TO VIEW 6 MORE

TOTAL LINKS TO THIS WEBSITE

14

OTHER SITES

investor.affiniagroup.com investor.affiniagroup.com

AFFINIA - SEC Filings

SEC Filing Keyword Search. View SEC Groupings descriptions. View Section 16 Filings (3,4,5). Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Quarterly report which provides a continuing view of a company's financial position. Report of unscheduled material events or corporate event. Annual report which provides a comprehensive overview of the company for the past year.

investor.affymetrix.com investor.affymetrix.com

Affymetrix - About Affymetrix - Investors - Investors

Powered by Affymetrix Partners. Aug 07 15 4:00 pm ET. The stock price performance shown on the quote above is not necessarily indicative of future price performance. Q2 2015 Affymetrix Earnings Conference Call. 160;at 5:00 pm ET. Q2 2015 Affymetrix Earnings Conference Call. Wednesday, July 29, 2015 . 5:00 pm ET  . Click here for webcast. Click here to add this event to your calendar. VP Investor Relations and Treasury. Affymetrix Reports Second Quarter 2015 Operating Results. SANTA CLARA, Calif.- (BU...

investor.afop.com investor.afop.com

Alliance Fiber Optic Products, Inc. - Investor Relations

Skip to Main Content. Annual Report and Proxy. Proxy Statement - Annual Meeting. At Alliance Fiber Optic Products, Inc. (NASDAQ: AFOP). View all ». Jul 22, 2015. AFOP Reports Record Quarterly Sales in Q2 2015; Guidance for Year-Over-Year Increases of 33% in Q3 2015. Jul 6, 2015. AFOP Announces the Second Quarter Preliminary Results With Record Revenues, and the Second Quarter Conference Call Invitation.

investor.agenusbio.com investor.agenusbio.com

Agenus Bio Investor Center |

Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. July 24, 2015. GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa. July 23, 2015. Agenus Reports Second Quarter 2015 Financial Results. July 20, 2015. Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1. July 16, 2015. Agenus to Report Second Quarter 2015 Financial...

investor.agilent.com investor.agilent.com

Agilent | Investor Overview

Q3 2015 Agilent Technologies Inc. Earnings Conference Call. August 17, 2015. 160;at 1:30 pm PT. AGILENT TECHNOLOGIES COMPLETES SPIN-OFF OF KEYSIGHT TECHNOLOGIES. On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business, now called Keysight Technologies. All of the outstanding shares in Keysight were distributed to Agilent shareholders on November 1, 2014. Keysight Investor Relations Website. August 17, 2015.

investor.agios.com investor.agios.com

Overview- Agios

Annual Report and Proxy. Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. 160; 2.23. Aug 06, 2015. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. Aug 05, 2015. Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015. Jul 30, 2015.

investor.ahbelo.com investor.ahbelo.com

A. H. Belo Corporation - Overview

About A. H. Belo. A H Belo Companies. Advertising with A. H. Belo. Second Quarter 2015 A. H. Belo Corporation Financial Results Conference Call - Transcript. The Dallas Morning News. Texas' leading newspaper and winner of nine Pulitzer Prizes; the. And Wanderful Media, LLC, owner of. A H Belo Corporation Announces Second Quarter 2015 Financial Results from Continuing Operations. A H Belo Corporation Announces Schedule for Second Quarter 2015 Financial Results Release and Conference Call. Â Â Past Events.

investor.ahgp.com investor.ahgp.com

Alliance Holdings GP, L.P. -Overview

About AHGP  . Investor Information  . Second Quarter 2015 Alliance Resource Partners, L.P. and Alliance Holdings GP, L.P. Earnings Conference Call. 160;at 9:00 am ET. Second Quarter 2015 Alliance Resource Partners, L.P. and Alliance Holdings GP, L.P. Earnings Conference Call. Tuesday, July 28, 2015 . 9:00 am ET  . Click here for webcast. Alliance Holdings GP, L.P. Reports Quarterly Financial Results and Increases Quarterly Distribution by 2.4% to $0.96 Per Unit. There are currently no events scheduled.

investor.airwarelabs.com investor.airwarelabs.com

Home Page

Airware Labs Corporation AIRW. Regulatory Reports and Filings. Break Through Breathing Technology. Airware interview with the American Urban Radio Networks. A Harnessing Plant-Based Essential Oils To Clean Up The Oxygen Supply. AIR SLEEP/SNORE got a shout out on ABC 10 Miami as a drug-free solution to improve sleep! Study finds cognitive therapy can improve sleep without use of medication. Airware Labs Featured on Drug Topics. AirWare Featured on NBC affiliate in Sacramento. Airware Labs Featured on.

investor.ais.co.th investor.ais.co.th

AIS Investor Relations

AIS ช ว ตในแบบค ณ. Result Announcement 2Q15: 3 Aug 2015. No of shares (million). No1 Thailand mobile operators, both in terms of subscribers and revenue market shares. The largest network coverage with over 15.000 cell sites nationwide. Successfully developing three distinctive brands targeting different customer profile. Maintain market share leader both in city and rural areas.Strong dividend payment with low debt profile. 2Q15 results : 2Q15 Financial result is now available. View or Pay my bill online.

investor.ait.co.th investor.ait.co.th

Advanced Information Technology Public Company Limited: IR Home

Keep up to date with the AIT's investors news. The investment in Campana Company. Resolutions of AGM 1/2017. Publication of the Annual General Shareholders Meeting (AGM) No.1/2017 invitation and Annual Report both in Thai. SET Opportunity Day Q4/2016: 16 Mar 2017. Opportunity Day is at 14:10 to 15:10, Meeting Room 603 , Stock Exchange of Thailand. Invitation to the Annual General Meeting 1/2017. Corporate Governance Year 2014. Annual General Meeting 1/2017. Annual Report Year 2016. 66 (0) 2275 9400.